Flavonoids are natural organic compounds that are derivatives of diphenylpropane. This group of polyphenols can be found in multiple natural sources and they exhibit a variety of biological effects. Despite the wide array of beneficial properties, the development of drugs based on these compounds is hindered by their low bioavailability. Although the substantial body of information available on strategies to enhance the solubility and bioavailability of flavonoids, this knowledge remains fragmented. Therefore, the aim of this study was to consolidate and systematize scientific data on methods for increasing the solubility and bioavailability of flavonoid compounds without changing their initial molecular structures. Throughout the investigation, it was determined that the most prevalent methods for increasing solubility and bioavailability include co-crystallization, formation of phospholipid and inclusion complexes, and the creation of nanostructures. Although there were no pronounced differences observed in enhancing solubility, the impact of these methods on pharmacokinetic parameters was established. It was found that the production of inclusion complexes and nanostructures leads to the greatest increase in the area under the pharmacokinetic curve by an average of 4.2 and 3.7 times, respectively. The least effect was noted for phytosomes, where this parameter for the modified forms exceeded the initial value by only 1.7 times. Phospholipid complexes exhibited a longer average half-elimination time than all other modifications, achieving a 2.1-fold increase. For nanostructures and micelles, a substantial increase in maximum concentration of the active substance in blood plasma was observed, reaching an average of 5.4 times for both types of modifications. During the systematization and generalization of the data, a high level of heterogeneity in solubility assessment methods across various studies was revealed, complicating comparisons of original data obtained by different researchers. The findings of this review are crucial for researchers investigating the bioavailability of flavonoid compounds and will facilitate the selection of the most effective methods based on the desired outcomes for solubility and bioavailability.
12 March 2025 in Journal of Pharmacy & Pharmaceutical Sciences
This study focuses on implementing a composition of the natural flavonoid dihydroquercetin (DHQ) with L-lysine in the treatment of thermal burns. The wound-healing activity of DHQ is well-known. The addition of amino acid to the composition increases the water solubility of the flavonoids, providing an opportunity to develop a spray dosage form. The research involved 60 male Wistar rats divided into five treatment groups. Sea buck oil served as a positive control. On day 14, the composition treatment group showed significant progress in wound healing, being 9.6 ± 2.0% ahead of the other groups in absolute terms. On day 35, treatment with the composition resulted in a significant decrease in relative wound area to 1.9 ± 0.9%, while in the negative and positive control groups, it was 10.7 ± 7.8% and 8.4 ± 4.9%, respectively. At the same time, the epidermal and dermal layers were found to be clearly distinguished in the composition treatment according to histological analysis. Numerous collagen fibres were clearly visible, and the active process of keloid scar formation was observed. An additive effect of the combined use of DHQ and L-lysine was observed (F = 0.21, p = 0.649). A natural next step is to develop the dosage form for the DHQ-L-lysine composition.
Background: Obesity is a global epidemic and a complex chronic disease affecting more than one billion patients, leading to severe health issues like diabetes, heart disease, and cancer. While lifestyle changes are the first-line treatment, they are often insufficient. Current medications may cause severe side effects, including muscle loss and vision problems. Objectives: This systematic review aims to generalize and evaluate data from preclinical studies on the effect of flavonoid dihydroquercetin (DHQ) on weight loss in experimental animals compared with placebo-treated animals. Methods: This systematic review was conducted in accordance with the PRISMA guidelines. The protocol was registered in the PROSPERO database in August 2025 (CRD420251129793). Risk of bias (RoB) was assessed by using SYRCLE’s tool. Results: In total, eight studies included in the systematic review involved 175 animals (14 treatment groups and 9 control groups). Calculation of correlations between the reported effect on weight change and initial weight showed a strong association between these rates (R −0.9883). The intensity of DHQ effect depended on the condition: There were strong negative correlations between DHQ dose and the observed effect in diabetes mellitus (R −0.9056), hepatic lipid dysmetabolism (R −0.9339), and hepatic fibrosis (R −0.9025) in mice and rats’ data together. Conclusions: Intake of DHQ in the course of one month and three months resulted in a decrease in animals’ weight by 5.24% ± 1.95% and 18.29% ± 1.96% (p < 0.0001), respectively. Taken together, our results suggest the rationality for further research of DHQ as an anorexigenic agent, focusing on the stereochemistry of this flavonoid and its bioavailability optimization.
Dihydroquercetin (DHQ) is a promising object for the development of a treatment for patients with obesity and prediabetes requiring a moderate therapeutic effect. This paper reports a clinical case of DHQ application in a 30-year-old Caucasian male and proposes a molecular mechanism of its anti-obesity effect. DHQ was administrated as a dietary supplement at a dose of 100–200 mg/day during 3 months with treatment interruption for 1 month. The data collected one month before the treatment were used as a control. The molecular aspects were studied via molecular docking with β3-adrenoceptor (ADRB3, PDB ID: 9IJE) and peroxisome proliferator-activated receptor γ (PPARG, PDB ID: 2ZNO) and molecular dynamic simulation under conditions mimicking a human cellular environment. A pronounced weight decrease up to 0.73 kg/week was observed during DHQ administration. The highest affinity to ADRB3 was observed for the non-ionized H2aH3e-conformation of 2S,3R-DHQ (–8.846 kcal/mol). Molecules with 2S-configuration demonstrate 0.332 kcal/mol higher affinity to PPARG compared to 2R-stereoisomers. The intermolecular complex with cis-DHQ demonstrated higher stability in molecular dynamics simulation. The insights gained from this study may contribute to our understanding of flavonoids not merely as antioxidants but also as active ingredients that selectively interact with receptors. If future investigations confirm these results, they may serve as a foundation for developing a new class of anti-obesity remedies that act via ADRB3.
20 April 2026 in Problems of Biological, Medical and Pharmaceutical Chemistry
Obesity is a distinct disease that leads to severe health issues like diabetes, heart disease, and cancer. The spread of this pathology can be compared to an epidemic. The search for medications for weight control remains an actual challenge for pharmaceutical and medical sciences. In particular, studying the anorexigenic effect of the flavanol dihydroquercetin (DHQ) is of special interest. Bibliographic databases contain a lot of studies reporting the dynamics of weight changes on the background of taking this flavonoid, and recent studies have shown that DHQ promotes weight loss. Therefore, the aim of this article is to assess the data of experimental studies on the effect of DHQ on the body weight of experimental animal model compared to control groups. The study results demonstrate statistically significant weight loss in mice and rats with various pathologies within the first month of DHQ administration. The biological effect of the flavonoid under the described conditions was comparable to the effect of GLP-1 receptor agonists. Thus, if the results of fundamental research are successfully translated into clinical practice, the use of this flavonoid will make it possible to reduce therapeutic doses of standard medications and will provide administration for patients requiring mild pharmacological intervention. This could improve the life quality of 483 million patients worldwide. Realization of this strategy would reduce the procurement and production of GLP-1 receptor agonists, which, given the high cost of treatment, would reduce the economic burden on the healthcare system. A systematic review identified a number of challenges for pharmaceutical science that require solutions for the successful development of a drug based on DHQ. In particular, future research should focus on studying the influence of flavanonol stereochemistry on its biological effect, as well as on identifying modifications with improved bio-availability and optimal dosage form.
Oral diseases cause a wide range of difficulties for patients. The natural bioactive compound dihydroquercetin (DHQ), which demonstrates regenerative, anti-inflammatory, antioxidative, and antibacterial effects, is of interest for their treatment. The combination of DHQ and l-lysine DHQ is “very easily soluble”. The aim of this study is to compare orally disintegrating tablets based on raw DHQ and on the DHQ-l-lysine composition. Following the guidelines outlined in the ICH Q8 (R2) standard, a fundamental quality target product profile and critical quality attributes were established. The Sediment Delivery Model (SeDeM) method was used to evaluate the substance suitability for direct compression. Quantitative analysis of the DHQ release was carried out by high-performance liquid chromatography, and infrared (IR) spectroscopy was performed using the attenuated total reflection technique without any prior sample preparation. The DHQ-l-lysine composition shows improved dimensions (4.12) and flowability (4.96). The release rate constants (Krelease) were 8.14 and 3.61%/min, while the half-release periods (t50%) were 6.14 and 13.85 min for tablets with DHQ (TF1) and DHQ-l-lysine compositions (TF2), respectively. The difference factor (f1) and similarity factor (f2) were 23.43% and 43.37%, respectively. The tablet manufacture had a critical impact on the characteristics of the IR spectra (the r values −0.8785 and 0.5474 for TF1 and TF2). The conducted study demonstrates the promise of using DHQ-l-lysine composition for developing effective dosage forms with improved technological characteristics and controlled release of the active substance.